LB Pharmaceuticals Inc (LBRX)
| Market Cap | 1.38B |
| Revenue (ttm) | n/a |
| Net Income | -38.95M |
| EPS | -2.59 |
| Shares Out | 28.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,158 |
| Open | 48.81 |
| Previous Close | 48.18 |
| Day's Range | 47.42 - 49.14 |
| 52-Week Range | 13.36 - 49.14 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 45.88 (-4.42%) |
| Earnings Date | Aug 11, 2026 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $45.88, which is a decrease of -4.42% from the latest price.
News
LB Pharmaceuticals announces $150M private placement
LB Pharmaceuticals (LBRX) announced that it has entered into a securities purchase agreement to sell 3,577,560 shares of its common stock and pre-funded warrants to purchase up to 715,513 shares…
LB Pharmaceuticals Announces $150 Million Private Placement
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
LB Pharmaceuticals expects to report results from NOVA-2 clinical trial in 2027
LB Pharmaceuticals (LBRX) announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophren...
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
LB Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $46 price target While antipsychotic therapies have been well established in schizophrenia treatment, LB-102 h...
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior V...
LB Pharmaceuticals initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of LB Pharmaceuticals (LBRX) with an Outperform rating and $45 price target Lead asset LB-102 should report positive Phase 3 NOVA-2 data in…
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizop...
Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102
Clear Street analyst Kaveri Pohlman keeps a Buy rating and a $45 price target on LB Pharmaceuticals (LBRX). The firm contends that Neumora Therapeutics (NMRA) Phase 3 KOASTAL failure has…
LB Pharmaceuticals Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
LB-102, a novel antipsychotic with improved potency and tolerability, is advancing through late-stage trials for schizophrenia, bipolar depression, and MDD. The drug shows promise for cognitive and negative symptoms, with a robust IP position and plans for a long-acting injectable.
LB Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
LB-102, a next-generation benzamide antipsychotic, is advancing through late-stage trials for schizophrenia, bipolar depression, and MDD, with strong efficacy, safety, and cognitive benefits. Multiple pivotal readouts are expected through 2029, supporting broad neuropsychiatric expansion.
LB Pharmaceuticals Transcript: AGM 2026
The meeting covered board introductions, two shareholder proposals, and voting. All director nominees were elected and the auditor appointment ratified. No questions were submitted, and voting results will be reported on Form 8-K.
LB Pharmaceuticals to Participate in Upcoming June Investor Events
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizoph...
LB Pharmaceuticals initiated with a Buy at Clear Street
Clear Street analyst Kaveri Pohlman initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The firm is citing its “high conviction” in LB-102, an oral…
LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
Roth Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $37 from $31 and keeps a Buy rating on the shares post the Q1 report. The firm has…
LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)
“With multiple clinical trials ongoing, our focus is on execution to support several clinical readouts over the next three years that have the potential to unlock tremendous value of LB-102…
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression
LB Pharmaceuticals Earnings release: Q1 2026
LB Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
LB Pharmaceuticals Quarterly report: Q1 2026
LB Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
LB Pharmaceuticals Slides: Investor presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
LB Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The company is focused on the neuropsychiatry space with a “novel, potentially groundbreaking var...
LB Pharmaceuticals Proxy statement: Proxy filing
LB Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
LB Pharmaceuticals Proxy statement: Proxy filing
LB Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
LB-102, a novel CNS therapeutic, is advancing through fully funded phase III and II trials in schizophrenia, bipolar depression, and adjunctive MDD, with data readouts expected from 2027 to 2029. The drug's differentiated mechanism, strong safety profile, and robust efficacy position it competitively for multiple indications.